Aspiriant LLC Has $235,000 Stock Holdings in Solventum Co. (NYSE:SOLV)

Aspiriant LLC decreased its stake in Solventum Co. (NYSE:SOLV) by 4.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,554 shares of the company’s stock after selling 151 shares during the quarter. Aspiriant LLC’s holdings in Solventum were worth $235,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. MML Investors Services LLC lifted its holdings in shares of Solventum by 3.2% in the third quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock valued at $373,000 after purchasing an additional 168 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its position in Solventum by 4.2% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock valued at $346,000 after buying an additional 200 shares during the period. IVC Wealth Advisors LLC lifted its stake in Solventum by 5.0% in the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after acquiring an additional 318 shares in the last quarter. KKM Financial LLC boosted its position in Solventum by 7.9% during the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after acquiring an additional 319 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. grew its stake in Solventum by 69.7% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 891 shares of the company’s stock valued at $59,000 after acquiring an additional 366 shares in the last quarter.

Analysts Set New Price Targets

Several analysts recently commented on SOLV shares. Wolfe Research began coverage on shares of Solventum in a report on Thursday, September 26th. They set a “peer perform” rating for the company. Piper Sandler lifted their target price on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Mizuho assumed coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target on the stock. Morgan Stanley lifted their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Stifel Nicolaus began coverage on Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, Solventum has an average rating of “Hold” and a consensus target price of $68.29.

Solventum Trading Up 0.6 %

SOLV opened at $73.94 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The stock has a 50-day moving average of $69.16 and a 200-day moving average of $65.85. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.15 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.23). The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.05 billion. Equities analysts forecast that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.